Funding Opportunity PAR-20-116 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Funding Opportunity RFA-AI-20-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This information will serve as a guide for the construction of new and improved candidate prophylactic HCV vaccines that will be assessed for immunogenicity and efficacy in appropriate animal models.

Competitive Salary: EMBL: Bioinformatician – Proteomics data pipelines Locatio Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Computer Scientist / Bioinformatician Location: Germany (DE)

Funding Opportunity RFA-MH-20-128 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.

The UW Advanced Research Computing Center (https://arcc.uwyo.edu/content/home) provides access to world-class computational resources, and the Wyoming INBRE…
From University of Wyoming - Sat, 22 Feb 2020 02:16:02 GMT - View all Laramie, WY jobs

Notice NOT-GM-20-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HS-20-002 from the NIH Guide for Grants and Contracts. This initiative will fund the dissemination and implementation of PCOR clinical and organizational findings into primary care practices to improve healthcare quality with a focus on cardiovascular care. AHRQ is particularly interested in applications from States with the highest cardiovascular disease (CVD) burden. The initiative will accomplish this goal by catalyzing the development of a sustainable, State-based external primary care quality improvement (QI) support infrastructure to expand the States current and future capacity to disseminate and implement PCOR evidence into primary care practice.

Notice NOT-GM-20-019 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-012 from the NIH Guide for Grants and Contracts

Competitive Salary: Dana-Farber Cancer Institute: Chronic lymphocytic leukemia (CLL) remains the most common leukemia of adults and is incurable. Several... MA - Massachusetts

Competitive Salary: EMBL: Marine Biocurator/Senior Marine Biocurator Location: Cambridge, Cambridgeshire, England

Notice NOT-DA-20-032 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-004 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-026 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-030 from the NIH Guide for Grants and Contracts

F. Hoffmann-La Roche AG: Roche Pharma Research and Early Development (pRED) translates extraordinary science into medical innovation through a diversity of technologies and t Switzerland (CH)

F. Hoffmann-La Roche AG: Roche Pharma Research and Early Development (pRED) translates extraordinary science into medical innovation through a diversity of technologies and t Switzerland (CH)

Notice NOT-MD-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-023 from the NIH Guide for Grants and Contracts